A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：ALLERGOLOGY INTERNATIONAL ISSN： 1323-8930 出版频率： Quarterly 出版社： JAPANESE SOCIETY ALLERGOLOGY, MY BLDG 4F, 1-13-3, UENO, TAITO-KU, TOKYO, JAPAN, 110-0005   出版社网址： http://ai.jsaweb.jp/ 期刊网址： http://ai.jsaweb.jp/ 影响因子： 5.836 主题范畴： ALLERGY;    IMMUNOLOGY 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Allergology International (AI) is the official journal of the Japanese Society of Allergology (JSA). It provides an international forum of basic and clinical research in allergology and immunology, especially aiming at advance excellence in research activities for allergology in Asia. AI has been selected for coverage in Thomson Scientific products and services. Beginning with Vol.61, No.1, information on the contents of this publication is indexed in Science Citation Index Expanded, Current Contents®/Clinical Medicine and others. Also, the SCImago Journal (& Country) Rank (SJR http://www.scimagojr.com/index.php), which is a free online portal that includes the journal information developed from the one contained in the Scopus database (Elsevier B.V.) covering nearly 18,000 journals. Cites per Doc. (2y) measures the scientific impact of an average article published in the journal, it is computed using the same formula that Thomson Reuters' impact factor TM. AI has succeeded to maintain more than 2 of this index equivalent to the impact factor TM. Considering this, the impact factor TM of AI, which will appear soon, is also expected to be more than 2. As such, Allergology International will make a deeper and higher impact on allergists worldwide! AI publishes original works in the fields of allergy, asthma, immunopathology, immunogenetics, immunopharmacology, mucosal immunity and immunology of infectious and connective tissue diseases. Aims and Scope Allergology International is the official journal of the Japanese Society of Allergology and publishes original papers dealing with the etiology, diagnosis and treatment of allergic and related diseases. Papers may include the study of methods of controlling allergic reactions, human and animal models of hypersensitivity and other aspects of basic and applied clinical allergy in its broadest sense. The Journal aims to encourage the international exchange of results and encourages authors from all countries to submit papers in the following four categories: Original Articles, Review Articles, Short Communications and Letters to the Editor. The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers and the Editor. Instructions to Authors Call for Papers We strongly encourage your contribution to our journal. We are looking forward to receiving excellent and informative manuscripts. Hirohisa Saito, Editor-in-Chief Submission of Manuscripts All articles submitted to the journal must comply with these instructions. Failure to do so will result in return of the manuscript and possible delay in publication. Manuscripts should be written so that they are intelligible to the professional reader who is not a specialist in the particular field. Where contributions are judged as acceptable for publication on the basis of scientific content, the Editor or the Publisher reserve the right to modify typescripts to eliminate ambiguity and repetition and improve communication between author and reader. If extensive alterations are required, the manuscript will be returned to the author for revision. Online Submission All manuscripts are to be submitted and reviewed electronically using the Manuscript Central (MC) system at http://mc.manuscriptcentral.com/ai-jsa. Covering letter Papers are accepted for publication in the journal on the understanding that the content has not been published or submitted for publication elsewhere. This must be stated in the covering letter. The authors must be cautious even for review articles. Each reproduction must be accompanied by the citation. Authors must also state that the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken. Experiments involving either human subjects or material of human origin should be carried out in accordance with the principles embodied in the Declaration of Helsinki of 1995 (as revised in Seoul 2008). All investigations on human subjects must include a statement that the subject gave a written informed consent and patient anonymity were preserved using documents and methods approved by the ethical review committee of the hospital. This statement must be given also in the text, Methods or elsewhere. Clinical trials such as pharmacological interventions should be preregistered to a public registry approved by WHO, for example, www.clinicaltrials.gov, or www.umin.ac.jp/ctr/index-j.htm. The disclosed information should include primary outcomes in order to prohibit post hoc analysis based on researchers' prejudice. This statement must be given also in the text. Authors should follow the guidelines for the care and use of laboratory animals. In the case of research involving recombinant DNA, experiments should be performed according to the guidelines issued by the authorized agency in the country in which the research was carried out. This statement should be given in the text. Conflict of interest disclosure Each author who is listed on the title page should declare any financial support or relationships that may pose conflict of interest. The corresponding author is required to confirm whether all authors have any conflicts of interest to declare, and to send the Conflict of Interest Disclosure Form (available at http://mc.manuscriptcentral.com/ai-jsa) to the Editorial Office by fax at+81-(0)3-5807-1702. Manuscripts cannot be processed until Conflict of Interest Disclosure Forms from the corresponding author have been received. Copyright Papers accepted for publication become copyright of Japanese Society of Allergology and all authors will be asked to sign a transfer of copyright form. In signing the transfer of copyright it is assumed that authors have obtained permission to use any copyrighted or previously published material. All authors must read, agree to the conditions outlined in the Copyright Transfer Form and must sign the Form. Articles cannot be published until a signed Copyright Transfer Form has been received. Published articles may not be published elsewhere, in English or any other language, without the permission of the Editor-in-Chief. Language Please write your text in good English. Authors may be requested to have the English of the manuscript checked and improved by language editing and copyediting services before submission. Reviewers are not expected to correct grammatical errors and any deficiency in this area may detract from the scientific content of the paper. Preparation of the Manuscript Submissions should be doubled-spaced on A4 page. The top, bottom and side margins should be 30 mm. All pages should be numbered consecutively in the top right-hand corner, beginning with the title page. Indent new paragraphs. Turn the hyphenation option off, including only those hyphens that are essential to the meaning. MS Word is preferred format for an electronic file of the manuscript that can be submitted via the Manuscript Central system at http://mc.manuscriptcentral.com/ai-jsa. Style Manuscripts should follow the style of the Vancouver agreement detailed in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, as presented in JAMA 1997; 277: 927-34. All measurements must be given in SI units as outlined in the latest edition of Units, Symbols and Abbreviations: A Guide for Medical and Scientific Editors and Authors (Royal Society of Medicine Press, London). Abbreviations should be used sparingly and only where they ease the reader's task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation. Upon its first use in the title, abstract and text, the common name of a species should be followed by the scientific name (genus, species and authority) in parentheses. However, for well-known species, the scientific name may be omitted from the article title. If no common name exists in English, the scientific name should be used only. At the first mention of a chemical substance, give the generic name only. Trade names should not be used. Allergen nomenclature should be referred to the list of allergens (http://www.allergen.org/) by International Union of Immunological Societies Allergen Nomenclature Sub-Committee. Parts of the manuscript For Original Articles the manuscript should be presented in the following order: title page; abstract and key words; introduction; methods; results; discussion; acknowledgements; references; figure legends; tables (each table complete with title and footnotes) and figures. Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter. Title page: The title page should contain (i) the title of the paper, (ii) the full names of the authors and (iii) the addresses of the institutions at which the work was carried out together with (iv) the full postal and e-mail address, plus facsimile and telephone numbers, of the author to whom correspondence about the manuscript, proofs and requests for offprints should be sent. (v) Conflict of interest should be disclosed. Even if there is no conflict of interest, the statement should be included. The title should be short, informative and contain the major key words. A short running title (less than 40 characters, including spaces) should also be provided. Abstract and key words: Articles must have a structured abstract that states in 250 words or less the purpose, basic procedures, main findings and principal conclusions of the study. Divide the abstract with the headings: Background, Methods, Results, and Conclusions. For Case Reports the abstracts should be structured with the headings: Background, Case Summary, and Discussion. The abstract should not contain references. Five key words should be supplied in alphabetical order below the abstract and should be taken from those recommended by the Index Medicus Medical Subject Headings (MeSH) browser list (http://www.nlm.nih.gov/mesh/meshhome.html). Text: Authors should use subheadings to divide the sections of their manuscript: Introduction, Methods, Results, Discussion, Acknowledgements, and References. Introduction: This section should include sufficient background information to set the work in context. The aims of the manuscript should be clearly stated. The introduction should not contain either findings or conclusions. Methods: This should be concise but provide sufficient detail to allow the work to be repeated by others. The source of material should be given in detail, where possible. Ethical considerations should be detailed. Results: Results should be presented in a logical sequence in the text, tables and figures; repetitive presentation of the same data in different forms should be avoided. The results should not contain material appropriate to the discussion. Discussion: This should consider the results in relation to any hypotheses advanced in the introduction and place the study in the context of other work. Acknowledgments: The source of financial grants and other funding should be acknowledged, including a frank declaration of the authors' industrial links and affiliations. The contribution of colleagues or institutions should also be acknowledged. Thanks to anonymous reviewers are not allowed. References: The Vancouver system of referencing should be used. In the text, references should be cited using superscript Arabic numerals in the order in which they appear. If cited only in tables or figure legends, number them according to the first identification of the table or figure in the text. In the reference list, the references should be numbered and listed in order of appearance in the text. Cite the names of all authors when there are six or less; when there are seven or more, list the first three authors followed by et al. Names of journals should be abbreviated in the style used in Index Medicus. Reference to unpublished data and personal communications should appear in the text only. For references to in press articles, a final manuscript file of the accepted article should be included in the supplementary files when submitting. Authors must confirm in their covering letter that articles cited as “In press” have been accepted for publication. References should be listed in the following form: Journal articles l.Colon AR, Ledesma BS, Pardo V, Sandberg DH. Viral potentiation of chemical toxins in the experimental syndrome of hypoglycemia, encephalopathy, and visceral fatty degeneration. Am J Dig Dis 1974; 19: 1091-104. Non-English journal articles 2.Wakabayashi K, Kakita A, Takahashi H, Obata K, Ikuta F.[Immunohistochemical study of synaptic vesicle-specific protein in Jakob-Creutzfeld disease brain]. Shinkei Kenkyu no Shimpo [Adv Neurol Sci] 1992; 36: 503-10 (in Japanese). Books 3.Antia FP. Clinical Dietetics and Nutrition, 2nd edn. London: Oxford University Press, 1973. Chapters in books 4.Weinstein L, Swartz MN. Pathogenic properties of invading micro-organisms. In: Sodeman WA Jr, Sodeman WA (eds). Pathologic Physiology: Mechanisms of Disease. Philadelphia: WB Saunders, 1974; 457-72. Tables: Tables should be self-contained and complement, but not duplicate, information contained in the text. Tables should be numbered consecutively in Arabic numerals. Each table should be presented on a separate file with a comprehensive but concise legend above the table. Tables should be double-spaced and vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses; all abbreviations should be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. The table and its legend/footnotes should be understandable without reference to the text. Figures: All illustrations (line drawings and photographs) are classified as figures. Figures should be cited in consecutive order in the text and can be submitted via Manuscript Central (MC) system at http://mc.manuscriptcentral.com/ai-jsa. Figures should be sized to fit within the column (81 mm) or the full text width (171 mm). Each figure should be presented on a separate file. Line figures should be supplied using Microsoft PowerPoint or painting software, such as Adobe Photoshop, by saving as high resolution (at least 1200 d.p.i.) EPS (Encapsulated PostScript), TIFF (Tagged-Image File Format), or JPEG format. Photographs should be supplied using Microsoft PowerPoint or painting software, such as Adobe Photoshop, by saving as high resolution (at least 300 d.p.i.) EPS, TIFF, or JPEG format. Photographs need to be cropped sufficiently to prevent the subject being recognized, or an eye bar used; otherwise, written permission to publish must be obtained. Magnifications should be indicated using a scale bar on the illustration. Color figures should be supplied using Microsoft PowerPoint or painting software, such as Adobe Photoshop, by saving as high resolution (at least 300 d.p.i.) EPS, TIFF, or JPEG format. Figure legends should be self-explanatory and typed on a separate sheet. The legend should incorporate definitions of any symbols used and all abbreviations and units of measurement should be explained so that the figure and its legend are understandable without reference to the text. (Provide a letter stating copyright authorization if figures have been reproduced from another source.) The MC system requires that the combined size of all uploaded files should not exceed 30MB. If your files exceed this limitation, you may contact the Editorial Office by e-mail at <info@jsaweb.jp>. Letters to the Editor Letters to the Editor are brief reports of clinical or laboratory observations without sufficient depth of investigation to qualify as original articles, and begin with the salutation “To the Editor". The average Letter to the Editor fills 2 pages in the printed journal, although manuscripts that exceed this may be occasionally accepted for publication at the Editors' discretion. In general, a Letter to the Editor should not exceed 1000 words, not including the figure legend(s) and references. The figure legend(s) should not exceed 60 words. It must have no more than ten references and a total of 2 figures and/or tables. Special note regarding case reports: Case reports will only be considered for publication in the Letters to the Editor section of the Journal. Publication Fees Page charges: There are no page charges for articles. Proofs: Proofs will be sent via post or e-mail and should be returned by the specified date. Alterations to the text and figures (other than the essential correction of errors) are unacceptable at proof stage. Offprints: Authors may order offprints on the appropriate form sent with the page proofs. An Offprint Order Form outlining the cost of offprints will be sent to the corresponding author with the page proofs. Offprints will be provided only if a completed Offprint Order Form is returned to the Japanese Society of Allergology's office by the specified date. Color figures: The cost of the color figures will be charged to the author except Review Article (Invited). Our requirements for submitted manuscripts that are not mentioned in the Instruction for Authors, are in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals by International Committee of Medical Journal Editors (ICMJE) available online at http://www.icmje.org. Editorial Board EDITOR-IN-CHIEF Hirohisa SAITO, Tokyo, Japan EDITORIAL BOARD Cezmi A AKDIS, Davos, Switzerland Koichiro ASANO, Tokyo, Japan Thomas BIEBER, Bonn, Germany Jean BOUSQUET, Montpellier, France Shigeharu FUJIEDA, Fukui, Japan Atsuki FUKUSHIMA, Kochi, Japan Stephen J GALLI, Stanford, USA Toshio HEIKE, Kyoto, Japan Stephen T HOLGATE, Southampton, UK Chein-Soo HONG, Seoul, Korea Kenji IZUHARA, Saga, Japan Tak H LEE, London, UK Akio MORI, Kanagawa, Japan Jae Won OH, Seoul, Korea Yusei OHSHIMA, Fukui, Japan Thomas AE PLATTS-MILLS, Charlottesville, USA Johannes RING, Munich, Germany Sergio ROMAGNANI, Florence, Italy Takahiro SATOH, Tokyo, Japan Robert SCHLEIMER, Chicago, USA Shinji SHIMADA, Yamanashi, Japan Kazuhiko TAKEUCHI, Mie, Japan Jun TAMAOKI, Tokyo, Japan Gary WONG, Hong Kong, China Kohei YAMAUCHI, Iwate, Japan Yukiyoshi YANAGIHARA, Kanagawa, Japan ADVISORY COMMITTEE K Frank AUSTEN, Boston, USA John BIENENSTOCK, Hamilton, Canada Alain DE WECK, Bern, Switzerland Leonardo M FABBRI, Modena, Italy Kimishige ISHIZAKA, Yamagata, Japan SGO JOHANSSON, Stockholm, Sweden A Barry KAY, London, UK Tadamitsu KISHIMOTO, Osaka, Japan Francois BM MICHEL, Montpellier, France Minoru OKUDA, Tokyo, Japan Mario RICCI, Florence, Italy Albert L SHEFFER, Boston, USA Reuben SIRAGANIAN, Bethesda, USA Robert F TOWNLEY, Omaha, USA